Publications by authors named "Ilya Smitienko"
Article Synopsis
- A study compared two ways of giving a medicine called tocilizumab to patients with a disease called Takayasu arteritis (TAK).
- They looked at 109 patients from different countries and found that both methods worked similarly well after 6 months, with about 69% showing improvement.
- However, patients who got tocilizumab as a shot under the skin had a higher chance of getting worse again compared to those who received it through an IV.
Article Synopsis
- This study evaluates the safety and effectiveness of TNF-α antagonists and tocilizumab in treating Takayasu arteritis (TAK) in 209 patients, primarily young women.
- Results show that both treatment options achieved a high rate of complete response (66% for TNF-α and 70% for tocilizumab) after 6 months, although older age was positively correlated with response while certain baseline symptoms were negatively associated.
- The incidence of treatment relapses and adverse effects was similar for both therapies, indicating that they are equally effective for managing refractory TAK over a median follow-up of 36 months.
Objectives: Certolizumab pegol (CZP) is a PEGylated antigen-binding fragment-fragment of a humanized mAb neutralizing TNF. It lacks Fc-fragment and has a very low potential to cross the placenta. We aimed to report the efficacy and safety of CZP in a case series of patients with refractory Takayasu arteritis (TA).
View Article and Find Full Text PDFObjective: Recently few reports have suggested a potential benefit of rituximab in patients with eosinophilic granulomatosis with polyangiitis (EGPA). However, the current evidence is limited. We describe the efficacy and safety of rituximab in six patients with relapsing EGPA.
View Article and Find Full Text PDF